AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02857751 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surf therapy
Description: The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
Study NCT02559115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT Scan
Study NCT03384082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic treatment
Description: treatment
Study NCT04270318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CH Pulpotomy, physiologic saline
Description: Pulp chamber was cleansed with physiologic saline for 30 s.
Study NCT02130635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 100 MCG
Description: 100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Study NCT04270318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CH pulpotomy, NaOCl
Description: Pulp chamber was cleansed with 5 % NaOCl for 30 s.
Study NCT02130635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 MCG
Description: 500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
Study NCT04270318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy, physiologic saline
Description: Pulp chamber was cleansed with physiologic saline for 30 s.
Study NCT04270318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTA pulpotomy, NaOCl
Description: Pulp chamber was cleansed with 5 % NaOCl for 30 s.
Study NCT02130635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device
Study NCT02130635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: Lactose administered using a matching dry powder inhaler device
Study NCT03631849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri implantitis sanitation surgery
Description: an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0.
Study NCT03631849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care
Description: descaling and maintenance of implants
Study NCT03188133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioral task : emotional priming
Description: emotional priming task on ambiguous visual stimuli
Study NCT03188133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral task : emotional priming
Description: emotional priming task on ambiguous visual stimuli
Study NCT00499161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New model of nursing care
Study NCT01726504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
Study NCT01726504 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electro-acupuncture
Description: Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
Study NCT00956800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accu-Chek 360 software
Description: Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
Study NCT00956800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal care
Description: Control group will receive 5 routine office visits in one year
Study NCT01173081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20mcg once daily for 16 weeks or until study endpoint is achieved.
Study NCT01173081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
Study NCT00213135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Description: Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
Study NCT00213135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Description: Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
Study NCT00213135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
Study NCT00771459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5 %
Description: Local infiltration analgesia
Study NCT00771459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local infiltration analgesia
Study NCT01125904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
Study NCT02142712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
Study NCT02142712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
Study NCT02142712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
Study NCT02142712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
Study NCT02142712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
Study NCT02012075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Carvedilol Sulfate
Study NCT02012075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Metoprolol Succinate
Study NCT04956367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma
Description: Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
Study NCT04956367 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma
Description: Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
Study NCT04956367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser with PRP
Description: CO2 laser with PRP
Study NCT04956367 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 laser with placebo
Description: CO2 laser with placebo
Study NCT03971058 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IXIARO®- Japanese Encephalitis vaccine
Description: Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
Study NCT02339454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active treatment group
Description: Energy Density - 0.09 mJ/mm2 Device: Active Applicator
Study NCT02339454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo Applicator
Study NCT01001624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melanil facial cream
Description: Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
Study NCT01001624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 2% cream
Description: Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
Study NCT03570671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spasm positive
Description: Investigators define the positive criteria for VSA on MDCTA as follows:~1. Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~2. Diffuse small diameter (\< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT.
Study NCT03570671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Spasm negative
Description: Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
Study NCT01664130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01664130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01664130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00881686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adenosine
Description: 1.5mg/Kg adenosine will be administered intravenously before surgery
Study NCT02819583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCAR-019 (anti-CD19 CAR-T cells)
Study NCT00567905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: main content is epigallocatechin gallate (EGCG, 58%)
Study NCT00567905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea extract
Description: main content is epigallocatechin gallate (EGCG, 58%)
Study NCT00660400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacitidine
Description: Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M\^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
Study NCT00660400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Cell Transplantation (HCT)
Description: Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~* Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~* The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~* All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant.
Study NCT03515590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion with solid droplets
Description: This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
Study NCT03515590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsion with liquid droplets
Description: This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
Study NCT03565679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDLINE RENEWAL PULSE OXIMETRY SENSORS
Description: An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
Study NCT03565679 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO-OXIMETRY SENSORS
Description: A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
Study NCT02258854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 gevokizumab
Description: Solution for subcutaneous injection
Study NCT03116971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
Study NCT04835051 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding promotion
Description: The intervention included training of health workers in private health facilities to provide in-person breastfeeding counseling to pregnant women and women with a child \<6 months during clinic visits. The health workers also offered a mobile phone support component for appointment reminders, breastfeeding SMS and WhatsApp messages, WhatsApp breastfeeding support groups, informational materials (posters and foldable pocket-sized cards), and family engagement activities. Breastfeeding-related mass media through television and radio spots was available state-wide, including to women in intervention and comparison facilities.
Study NCT02094612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quotient®
Description: Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
Study NCT02094612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinic ADHD Care
Description: Usual ADHD care as provided by the clinic
Study NCT04258761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: Active test article
Study NCT03248960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iTreat Flu A+B Test
Description: The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
Study NCT03248960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ellume.lab Flu A+B Test
Description: The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
Study NCT03248960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Description: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
Study NCT03248960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Viral culture
Description: Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
Study NCT03298048 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
Study NCT03298048 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mid fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
Study NCT03298048 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High fecal microbiota dose
Description: receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
Study NCT04096404 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genotype- based personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
Study NCT04096404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non genetic personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
Study NCT04096404 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non genetic personalised advice
Description: Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
Study NCT02698852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme
Description: Stent platform: cobalt-chromium alloy
Study NCT03116971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.